1 2	Assessing the impact of the Gamma variant on COVID-19 Patient admissions in a Southern Brazilian				
3	tertiary hospital - A comparison of dual pandemic				
4	phases				
5 6	Natalia R Domino ^{1¶} , Bruna A Lapinscki ^{2¶} , Felipe Zhen ¹ , Guilherme Yamaguto ¹ ,				
7	Emanueli C S Costa ¹ , Vitor L Moriya ¹ , Luciane A Pereira ³ , Ricardo Petterle ⁴ , Meri B				
8	Nogueira ³ , Sonia M Raboni ^{1,4*}				
9 10	¹ Infectious Diseases Division, Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, Brazil				
11 12 13	² Microorganisms Research and Molecular Biology Laboratory, Universidade Federal do Paraná, Curitiba, Brazil				
14 15	³ Virology Laboratory, Universidade Federal do Paraná, Curitiba, Brazil				
16 17 18	⁴ Department of Integrative Medicine, Universidade Federal do Paraná, Curitiba, Brazil				
19					
20	* Corresponding author				
21	E-mail: sraboni@ufpr.br (SMR)				
22	[¶] These authors contributed equally to this work.				
23					
24	Funding: This study did not receive any funding				

26 Abstract

27 Since the first case of COVID-19, Brazil has undergone infection waves with distinct 28 characteristics. The description of new variants has alerted the emergence of more 29 contagious or virulent viruses. The variant of concern Gamma emerged in Brazil and 30 caused an epidemic wave, but its spread outside the country was limited. We report the 31 clinical-epidemiological profile of hospitalized patients with COVID-19 by comparing two 32 periods. A retrospective cohort study was performed. The primary outcome was to assess 33 individuals with COVID-19 admitted in wards and intensive care units at CHC-UFPR 34 between March 2020 and July 2021, correlating demographic, clinical-epidemiologic, and 35 survival data with the most prevalent viral variant found in each period. We used 36 Kaplan-Meier analysis to estimate the probability of survival and receiver operating 37 characteristic curves to evaluate laboratory tests to find a cutoff point for poor outcomes. 38 Data from 2,887 individuals were analyzed, 1,495 and 1,392 from the first and second 39 periods, respectively. Hospitalization predominated among males in both periods, and the 40 median age was significantly lower in the second one. The frequency of comorbidities was 41 similar. Various demographic factors, clinical assessments, and laboratory tests were 42 examined in relation to greater severity. When comparing the two studied periods, we 43 observed predominance of the Wild virus during the first wave and the Gamma variant 44 during the second, with no significant difference in outcomes. The findings suggest that 45 despite the association of many factors with increased severity, the temporal variation 46 between the two periods did not result in a notable divergence in the measured outcomes. 47 The COVID-19 pandemic has lasted for a long time, with periods marked by peaks of 48 cases, often caused by the emergence of viral variants, resulting in higher infection rates 49 and rapid dissemination but, for variant Gamma, no apparent greater virulence.

50 Background

51 The COVID-19 pandemic caused by the new coronavirus (*Severe Acute* 52 *Respiratory Syndrome Coronavirus 2* - SARS-CoV-2) has been one of this century's most 53 significant global health challenges. It was responsible for approximately 760 million cases 54 and more than 6.8 million deaths worldwide until March 2023. [1] With the United States 55 leading the number of cases and Brazil ranking sixth, the American continent is the second 56 most affected by the pandemic. [1]

57 Similar to other countries, Brazil has had fluctuations in the number of cases and 58 fatalities since the first documented COVID-19 case in February 2020. Although the 59 pandemic has reached virtually every country, it has not occurred equally worldwide. In 60 some countries, the waves were shorter and more intense than in other countries. For 61 instance, Brazil was still in the second wave, whereas Iran was affected by four waves 62 until March 2021. [2] The population's susceptibility, restriction measures, health services 63 responses, and SARS-CoV-2 transmission rate were influential in determining the 64 occurrence and severity of the waves. [3]

65 Late in 2020, Brazil experienced a new rise in hospital admissions. Concurrently, 66 the description of new variants of interest (VoI) and variants of concern (VoC) raised the 67 hypothesis that a more contagious or virulent variant could explain the increase in number 68 of cases. [4] The B.1.195 SARS-CoV-2 strain was introduced in Brazil at the beginning of 69 the pandemic and was soon replaced by variant B.1.1.28. [5] Variant of concern Gamma 70 was first detected in four Japanese travellers who returned from Brazil in early 2021, [6] 71 and became more prevalent as the second wave progressed. When the Gamma variant 72 first emerged in northern Brazil, it was associated with mutations that increased viral load 73 and transmissibility, and it took less than three months for it to become dominant. [4]

Any individual can be affected by COVID-19, and up to 20% of those who are symptomatic may progress to severe disease. Older adults and individuals with chronic diseases are the most vulnerable to present severe and critical disease. [7–9] As a result,

they were the most prevalent group in terms of hospitalizations during the first wave. [8– 10] In the second wave, an increase in hospitalization among young and not chronically ill individuals raised the hypothesis of a shift in the characteristics of patients requiring hospitalization. [11] Thus, the present study aimed to examine the clinical and epidemiological characteristics of individuals hospitalized with COVID-19 during two pandemic periods caused by distinct VOC of the SARS-CoV-2 in a tertiary referral hospital in southern Brazil.

84 Material and methods

85 Study design

86 A retrospective cohort study was conducted at Complexo Hospital de 87 Clínicas/Universidade Federal do Paraná (CHC-UFPR), a tertiary academic hospital in 88 Paraná, southern Brazil. The study has received approval from the Ethics Committee for 89 Human Research of the Complexo Hospital de Clínicas da Universidade Federal do 90 Paraná (#n 51400121.9.0000.0096). The data collection was conducted after obtaining 91 ethical approval from the committee on September 14, 2021, continuing until August 31, 92 2022. Subsequent to data inclusion in the database, all participants were assigned unique 93 numerical identifiers to ensure their complete anonymity and to safeguard their identities 94 from all subjects involved. Due to its retrospective nature, the informed consent was 95 waived.

The study was conducted with a convenience sampling of patients hospitalized in respiratory units at CHC-UFPR suspected of COVID-19 disease and patients in other critical units identified with B34.2 ICD 10 (infection by SARS-CoV-2 of unspecified location) between March 11th, 2020 and August 1st, 2021. The inclusion criteria were patients with confirmed or probable COVID-19 disease. The exclusion criteria were patients under the age of 18, those who tested positive for SARS-CoV-2 infection due to elective inpatient

102 care, those whose symptoms were attributed to other causes, and patients with missing103 data.

104 Clinical and epidemiological characteristics of patients hospitalized due to COVID-105 19 at two different epidemiological moments of the pandemic were compared. The first 106 moment comprised the period between March 11th, 2020 and February 16th, 2021, and the 107 second comprised the period between February 17th, 2021 and August 1st, 2021. The 108 cutoff date was chosen because the first COVID-19 infection in Curitiba by the Gamma 109 variant was confirmed on February 17th, 2021.

Subsequently, clinical and epidemiological characteristics were assessed to identify risk factors associated with the progression to critical illness and trace survival curve comparisons between the first and second periods.

113 Data collection

Epidemiological, clinical, and outcome data were collected based on a standard notification form for severe acute respiratory syndrome (SARS) from the Influenza Epidemiological Surveillance Information System (SIVEP Influenza), a national database used to monitor cases of respiratory infections. Chest computed tomography (CT) data and other relevant clinical information were obtained through the Hospital's Computerized System.

120 **Definitions**

121 The COVID-19 case was classified as confirmed, probable, or discarded, as 122 presented in Table 1.

Classification	Criteria
Confirmed case	 SARS-CoV-2 RT-PCR positive or, SARS-CoV-2 antigen test positive or, IgM reagent for SARS-CoV-2 and chest computed tomography (CT) with typical COVID-19 findings and COVID-19 clinical features.

123 Table 1. COVID-19 classification criteria.

Probable case	 IgM reagent for SARS-CoV-2 and chest computed tomography (CT) or, IgM reagent for SARS-CoV-2 and COVID-19 clinical features.
Discarded	Do not meet any of the above-mentioned criteria.

124

RT-PCR = Reverse Transcription Polymerase Chain Reaction

125

126

127 The presence of two symptoms of fever, cough, dyspnea, and desaturation was 128 considered clinically compatible with COVID-19. Findings consistent with SARS-CoV-2 129 infection identified on chest CT included ground-glass consolidations, predominantly 130 peripheral, and involvement of multiple lobes. All CT scans were analyzed and interpreted 131 by a radiologist, and the request for the exam was the assistant physician's decision. For 132 the evaluation, only the first laboratory exams performed at the patient's admission (or, in 133 the case of nosocomial infection, those closest to the date of onset of symptoms) were 134 considered.

A Clinical Progression Scale was used to classify the disease severity. The score ranges from 0 to 10, and the parameters include level of medical assistance (outpatient, ward, or intensive care unit) and oxygen supplementation (no need for oxygen supplementation, nasal catheter supplementation, high-flow nasal cannula, non-invasive ventilation, or orotracheal intubation). Scores 4 and 5 were classified as moderate, and scores above 6 were classified as severe disease. [12] The Charlson Comorbidity Index (CCI) was used to categorize the studied sample according to the comorbidities. [13]

142 Virus genotyping

Virus genotyping was performed on clinical samples from patients included in the study who had a quantification cycle (Cq) value <35 on the SARS-COV-2 RT-qPCR diagnostic.

The viral RNA was isolated from the clinical sample using the Extracta 32 automated extraction system with the EXTRACTA DNA and viral RNA kit (Loccus, SP, Brazil) according to the manufacturer's guidelines.

We used two probe-based genotyping systems to characterize SARS-CoV-2 variants. The first identified Alpha, Beta or Gamma, and Wild type. The second one determined the Delta variant and differentiated Beta from Wild-type, Gamma, and Zeta. RT-qPCR reaction was performed in the GoTaq[™] Probe 1-step RT-PCR system (Promega Bio Sciences, LLC. San Luis Obispo, CA, USA) according to the manufacturer's guidelines, with an input of 2.5uL RNA in a total reaction volume of 10uL. [14]

155 Data analysis

156 Statistical analyses were performed using the R Studio software, version 3.6.1. A 157 descriptive analysis showed the clinical, epidemiological, laboratory, and molecular 158 features. Data from quantitative variables were presented as medians and interguartile 159 range (IQR). Univariate analysis was performed using Fisher's exact and Chi-squared 160 tests for categorical variables. Mann-Whitney and Kruskal-Wallis rank sum tests with 161 Tukey's multiple post hoc comparisons were used for continuous variables, as appropriate. 162 We used Kaplan-Meier analysis to estimate the probability of survival and log-rank testing 163 for between-group comparison. Receiver operating characteristic (ROC) curves were built 164 to evaluate laboratory tests to find a cutoff point for poor outcomes. To evaluate risk factors 165 associated with the outcomes, adjusted OR (aOR) was calculated using the multivariate 166 model with a stepwise selection of variables, with a cut-off point of p<0.2. All statistical 167 tests were two-sided, with significance set at p < 0.05. A confidence interval (CI) of 95% 168 was used to adjust the estimates.

169 **Results**

170	A total of 4,546 individuals over the age of 18 were hospitalized in COVID-19
171	settings from March 11 th , 2020 to August 1 st 2021 (Figure 1). The first wave was from
172	March 11 th , 2020 to February 16 th , 2021 (a total of 343 days), and the second wave from
173	February 17 th , 2021 to August 1 st 2021 (165 days).

174

175 Fig 1. Flow-chart of study design.

176

Figure 2 shows the dynamics in the number of cases for the city of Curitiba, PR, (Brazil), the hospitalizations at CHC-UFPR, and the viral variant detection in the region over the same time period. As observed, Wild virus and Gamma variant predominated in the first and second studied periods, respectively.

181

Fig 2. Temporal distribution of COVID-19 cases in Curitiba (Brazil), hospital admissions, and viral genotype.

184

185 Clinical and demographic characteristics of the study 186 population

187 The overall median age was 56 years (IQR 44-66), with a predominance of men 188 (53.6%) and white race (89.6%). Overall, 2,359 (81.7%) patients reported having prior 189 diseases, the median Charlson Comorbidity Index score was 2 points (IQR 1-4). 190 Cardiovascular diseases were the most common comorbidities (46.1%), followed by type 2 191 diabetes (25.8%) and obesity (17.9%). The median time of symptom onset was 9 days 192 (IQR, 6-12) before hospitalization. The median time of hospitalization and mechanical 193 ventilation were 7 (IQR 4-16) and 8 (IQR 4-17) days, respectively. Regarding disease 194 severity, 1,109 (38.4%) individuals had severe disease, while 1,093 (37.9%) were admitted

to critical units; 641 (22.2%) patients died during hospitalization, while 77.8% weredischarged.

Comparison of clinical and demographic data between the first and second waves

199 Comparative analysis showed a predominance of men in both waves, 54% in the 200 first and 53.2% in the second. There was a significant reduction in median age in the 201 second wave (52 years, IQR 42-63) compared to the first (59 years, IQR 47-68 years), 202 p<0.001. The Wild strain was more prevalent in the first wave (78%), while Gamma variant 203 was more prevalent in the second wave (95.3%).

204 Table 2 summarizes the clinical and demographic characteristics of participants 205 included in the study, divided by pandemic waves. The frequency of comorbidities was 206 similar in both periods. In the second wave, there was a lower prevalence of 207 cardiovascular disease (42.2% versus 49.7% in the first wave, p<0.001) and type 2 208 Diabetes Mellitus (22.4% versus 28.9% in the first wave, p<0.001). There were more 209 hospitalizations among obese individuals in the second wave compared to the first (23% 210 versus 13.2%, respectively; p<0.001). Further, the Charlson Comorbidity Index median 211 score in the first wave was 3 (IQR 1-4), while in the second wave was 2 (IQR 0-4), 212 p<0.001.

Table 2. Baseline characteristics by pandemic wave of individuals hospitalized at Complexo Hospital de Clínicas UFPR, from March 11th, 2020 to August 1st, 2021.

	First pandemic wave n (%)	Second pandemic wave n (%)	p value
Median age (in years)	59 (IQR 47-68)	52 (IQR 42-63)	<0.001
Sex			
Female	687 (46)	652 (46.8)	0.6602
Male	808 (54)	740 (53.2)	
Race (n)			0.0022

White	1285 (87.9)	1264 (90.8)	
Non-white	177 (12.1)	118 (8.7)	
Genotype (n)	369	169	
Wild	288 (78.1)	2 (1.2)	
Zeta	52 (14.1)	5 (2.9)	<0.001
Gamma	27 (7.3)	161 (95.3)	
Alpha	2 (0.5)	1 (0.6)	
comorbidities			
Cardiovascular diseases	743 (49.7)	588 (42.2)	<0.001
Hematological diseases	27 (1.8)	21 (1.5)	0.632
Liver diseases	37 (2.5)	26 (1.9)	0.323
Asthma	59 (3.9)	60 (4.3)	0.691
Type-2 diabetes	432 (28.9)	312 (22.4)	<0.001
Neurological diseases	88 (5.9)	66 (4.7)	0.199
Lung diseases	116 (7.8)	54 (3.9)	<0.001
Immune diseases	52 (3.5)	32 (2.3)	0.076
Kidney diseases	73 (4.9)	41 (2.9)	0.011
Obesity	197 (13.2)	320 (23)	<0.001
espiratory support			
None	117 (7.8)	66 (4.7)	
Non invasive	820 (54.8)	840 (60.3)	<0.001
Invasive	558 (37.3)	486 (34.9)	
isease severity			
Mild	927 (62)	851 (61.1)	0.658
Severe	568 (38)	541 (38.9)	
Outcome			
Discharge	1170 (78.3)	1076 (77.3)	0.564
Death	325 (21.7)	316 (22.7)	

216

There was no significant difference in the frequency of reported symptoms between the waves, and the most common symptoms were desaturation (78.9% in the first wave and 94.1% in the second), dyspnea (80.8% and 80.5%), and cough (62.2% and 58.8%), as shown in Figure 3.

221

Fig 3. Comparison between the frequency of the reported symptoms at the time of hospital admission during the first and second pandemic waves.

224

225 In the first pandemic wave, the median time from the onset of symptoms to hospital 226 admission was 8 days (IQR 5-11), while in the second wave, it was 10 days (IQR 8-12); 227 p<0.001. The length of hospitalization was similar, 8 days (IQR 4-16) and 7 days (IQR 228 4-16) in the first and second waves, respectively; p=0.684. The length of intensive care 229 unit (ICU) stay was 9 days (IQR 4-18) in the first wave and 10 days (IQR 4-21) in the 230 second wave, p=0.257, and the median time on mechanical ventilation was 7 (IQR 3-15) 231 and 10 (IQR 5-21) days in the first and second waves, respectively, p<0.001. The median 232 time from the onset of symptoms to orotracheal intubation was 8 (IQR 5-12) and 10 (IQR 233 (8-13) days in the first and second waves, respectively, p<0.001. The proportion of patients 234 that did not require oxygen support was higher in the first (7.8%) than in the second wave 235 (4.7%): p<0.001. Regarding disease severity, there was no difference between the two 236 pandemic waves, and the proportion of patients admitted to the ICU was 40.3% in the first 237 wave and 35.3% in the second. Similarly, no significant difference was observed in in-238 hospital fatality rate in both waves (21.7% in the first wave versus 22.7 in the second; 239 p=0.5642). In the second wave, there was an increase in hospitalizations of individuals 240 aged 31 to 40 and 51 to 60 years with severe illness, both with p < 0.05 when comparing 241 the severity of the disease across age groups. Additionally, during the first wave, a higher

- severity of illness was observed among age groups between 61 and 70 years, between 71
- and 80 years, and those aged over 80 years, all with p < 0.05.
- 244 Overall, 78.6% of the laboratory samples were collected within 48 hours after
- admission. Patients admitted during the second wave had significantly higher inflammatory
- test values. Table 3 summarizes the laboratory results.

Table 3. Laboratory test results of individuals hospitalized at CHC-UFPR from March 11th, 2020 to August 1st, 2021.

Laboratory results	First pandemic wave Median (IQR)	Second pandemic wave Median (IQR)	p value
Lymphocytes count (NR 0,8-4,9x10 ³ /uL)	1310.29 (569.25-1326)	980.59 (519.5-1198.5)	<0.001
Total bilirubin (NR <1.2mg/dL)	0.44 (0.33-0.64)	0.46 (0.32-0.64)	0.8884
Creatinine (NR 0.72-1.25mg/dL)	0.86 (0.74-1.18)	0.80 (0.70-1.04)	<0.001
Aspartate aminotransferase (NR 5-34 U/L)	37 (25-57)	41 (28-65)	<0.001
Alanine aminotransferase (NR 0-55 U/L)	39 (23-63)	44 (28-75)	<0.001
DHL (NR 125-220 U/L)	383 (289-503)	423 (328-559.5)	<0.001
Ferritin (NR 4.63-204 ng/mL)	1079.26 (478-2023.49)	1246.36 (620.34-2487.88)	<0.001
CRP (NR ≤0.5 mg/dL)	7.29 (3.26-13.73)	9.51 (4.67-16)	<0.001
Procalcitonin (NR<0.5 ng/mL)	0.21 (0.08-0.72)	0.16 (0.07-0.6)	0.128
D-dimer (NR <0.55 mg/L)	1.06 (0.56-2.4)	1.06 (0.59-2.61)	0.453

249 NR = normal range. CRP = c-reactive protein. DHL = lactate dehydrogenase

250

251

252 Disease Severity Analysis

253 Univariate analysis of factors related to disease severity shows a higher median age

in patients with severe disease compared to those with moderate disease (59 versus 53

255 years, respectively; p<0.001). Male sex was also significatively related to severe disease, 256 p=0.004. The Charlson Comorbidity Index score was higher in the severe disease group, 257 with 3 points versus 2 points in the moderate disease group, p<0.001. Hospitalization 258 length was longer in patients with severe disease (15 days; IQR 9-26) compared to those 259 with moderate disease (5 days; IQR 3-9), p<0.001. Similar findings were observed for the 260 length of ICU stay (10 days [IQR 4-20] in severe disease versus 4 days [IQR 2-6] in 261 moderate disease; p<0.001). Higher values of ferritin (median 1549ng/mL [IQR 682.5-262 2885.75ng/ml]; p<0.001) and c-reactive protein (CRP) (median 12.2mg/dL [IQR 6.46-263 16ng/ml]; p<0.001) were also associated with severe disease.

- Table 4 shows the multivariate analysis of factors associated with disease severity.
- Age, sex, and obesity remained independent risk factors for severe disease.

266 Table 4. Multivariate analysis of predictors associated with disease severity.

Variables	Odds ratio	CI (95%)	p value
Age	1.01	1-1.02	0.044
Male	1.23	1.03-1.46	0.021
Charlson Comorbidity index score	1.11	1.03-1.2	0.005
Fever	1.22	1.03-1.46	0.025
Neurologic disease	1.68	1.09-2.6	0.020
Obesity	2.14	1.71-2.68	<0.001
Length of hospital stay	1.10	1.09-1.11	<0.001

- 267 Abbreviations: CI, confidence interval.268
- 269

270 Outcome Analysis

Patients discharged were significantly younger and more likely to be female compared to those who died (median 53 years versus 65 years, p<0.001; and p=0.0032 for sex), but no differences were observed for race. Mortality was more frequent among patients with higher Charlson Comorbidity Index scores, and among those with kidney and

275 cardiovascular diseases. Although obesity was a risk factor for disease severity, no
276 significant difference was observed in the fatality rate. Also, no differences in outcomes
277 were found when the genotypes were compared. Furthermore, patients who died were
278 admitted significantly earlier to the hospital, and the median time between hospital
279 admission and the outcome was longer.

In the multivariate analysis, age, male sex (OR 1.3, Cl 1.03-1.63, p=0.024), disease
severity classification (OR 5.04, Cl 2.19-10.52, p<0.001) and need of invasive ventilatory
support (OR 5.64, Cl 2.81-12.65, p<0.001) remained as independent risk factors for death.

283 Comparing the laboratory tests, patients who died had more pronounced 284 lymphopenia and higher values of lactate dehydrogenase (DHL), ferritin, CRP, and d-dimer 285 compared to those who survived. Receiver operating characteristic (ROC) curves were 286 built to analyze laboratory tests in order to determine a cutoff point for poor outcomes. A 287 value of 10.28mg/L for CRP revealed a sensitivity and specificity for worst outcomes of 288 61.3% and 62.9%, respectively (area under the curve [AUC]=0.655, 95% CI 0.628-0.681). 289 Creatinine exhibited a statistically significant difference in the outcome despite being 290 somewhat over the reference value, with a median of 1.92mg/dL for patients who died. 291 Moreover, values above 1.05mg/dL demonstrated 80.1% specificity but only 57.1% 292 sensitivity for adverse outcomes (AUC = 0.717, 95% CI 0.690-0.745). Age \geq 58.5 years, 293 Charlson Comorbidity Index score ≥ 2.5, ferritin levels ≥ 369.35ng/mL, DHL level ≥ 294 432.5U/L, and D-dimer levels \geq 1.25mg/L were related to poor outcomes (AUC values of 295 0.708, 0.696, 0.613, 0.685, and 0.678, respectively) (supplementary material).

Figure 4 shows a comparison of survival rates for the first and second waves, and no significant differences were found.

298

Fig 4. Kaplan-Meier survival analysis of patients admitted at CHC-UFPR comparing the first and second pandemic waves.

302 At the end of the year 2020, there was an increase in the number of cases. It 303 occurred at a point in time when the learning curve for managing the disease had already 304 become better established, alongside the implementation of corticosteroid usage 305 protocols. Taking this into consideration, a comprehensive sub-analysis was conducted to 306 compare the outcomes between two distinct periods: November 1st, 2020, to February 16th, 2021, and February 17th, 2021, to August 1st, 2021. Despite the temporal shift, the 307 308 results revealed that there was no statistically significant difference in outcomes between 309 these two timeframes (p = 0.2175). This suggests that the observed results are consistent 310 across both periods, and the temporal variation did not have a substantial impact on the 311 measured outcomes.

312 **DISCUSSION**

313 The COVID-19 pandemic has had a profound impact on health services and also on 314 socio-economic aspects worldwide. It is a novel disease caused by an emerging pathogen 315 and has been present for approximately three years. During this period, we faced 316 pandemic waves caused by the emergence of viral variants as a result of persistent viral 317 replication independent of natural, passive, or active immunity. In Brazil, between the first 318 and second pandemic waves, in which Wild virus and Gamma variant prevailed, 319 respectively, frontline health care professionals reported perceiving more severe cases 320 and excessive work overload in the second wave. In this study, seeking to evaluate the 321 impact of these two events, we analyzed data from a single tertiary facility to compare the 322 hospitalizations between the first two waves of the COVID-19 pandemic.

Overall, a significant difference was observed in patients' age, who were younger in the second wave compared to the first wave. Despite chronic diseases being more prevalent in the first wave, obesity was significantly more prevalent in the second wave. However, no significant difference was observed in the fatality rate, which was

327 approximately 22%. [8,10,15] Other studies also found a decrease in fatality rate 328 throughout the pandemic. [2]

329 The first reports describing the clinical and epidemiological characteristics of 330 COVID-19 showed high hospitalization rates among men and older adults. [9,16] 331 Subsequent studies showed that advanced age and male sex were associated with more 332 severe disease and the potential need for mechanical ventilation and admission to critical 333 units, regardless of pre-existing comorbidities. [17] A Mexican study showed that being 334 above the age over 65 was associated with a higher risk of hospitalization, especially 335 when obesity was present, [18] and a study from India showed a significant association 336 between advanced age and the risk of progressing to severe and critical disease. [19] 337 Immunosenescence is responsible for changes in the innate and adaptive immune 338 response, and advanced age is naturally related to poor immune responses. Differences in 339 the immune system, sex hormones, physiological factors, and lifestyle have been linked to 340 a higher risk of poor outcomes in men. [20]

341 Regarding comorbidities, a Brazilian population-based study showed that 16% of 342 individuals did not have comorbidities, [8] while an observational study from the United 343 States showed that 84,7% of the patients had at least one comorbidity at admission. [21] 344 Since the median age found in our study was lower than previously reported in the 345 literature and since older people tend to have more comorbidities, these may explain why 346 our study found more patients without comorbidities. Similar to what was previously 347 reported, the median time from symptom onset to hospitalization varied between 6 and 8 348 days. [8,15]

The overall fatality rate found in this study was considerably lower than those reported in other studies, which can reach over 40%. [22] A national study conducted in Brazil compared the characteristics of hospitalizations during the pandemic's early months across the country's five macroregions and found a nationwide fatality rate of 38% and

353 31% in the Southern region. [8] Lower fatality rates were observed in studies conducted at 354 later phases of the pandemic, [15] which may suggest a positive learning trend and more 355 readily available physical and professional infrastructure. Adopting health care protocols 356 based on scientific evidence, such as using a high-flow nasal cannula in hospital wards, 357 [23] using corticosteroids and a qualified multidisciplinary health care team contributed to 358 the better results observed in this study.

359 Similar to the findings of an African population-based study, this comparative 360 analysis showed a rise in the median time from the symptom onset to hospital admission 361 in the second wave compared to the first, showing a bed shortage and a healthcare 362 system overload. [24] This hypothesis may be supported by the increase in the median 363 time of mechanical ventilation usage in the second wave without an increase in the length 364 of ICU stay, suggesting a higher turnover of ICU beds to fulfill the demand for this level of 365 care. Furthermore, the lack of beds in critical units may have delayed patients' intubation 366 at the appropriate moment, resulting in more severe cases being intubated and extending 367 the duration of mechanical ventilation.

368 As shown in previous reports, there was a reduction in the median age of 369 hospitalized individuals in the second wave compared to the first wave. [11] A Mexican 370 study compared the first three waves of the pandemic and showed an increase in the risk 371 of hospitalization among young patients throughout the waves, with a significant higher OR 372 in the age group of 25-29 years in the third wave compared to the age group above 45 373 years in the first wave. [2,20] The median age of hospital admissions was reduced by 374 nearly ten years, and there was a 7% increase in hospital admissions among individuals 375 aged 0 to 19. [18,20] Some hypotheses, such as previous infection immunity and 376 vaccination coverage, may explain this finding. In Curitiba, the COVID-19 vaccination 377 began on January, 2021, for older adults, reaching the age group of 65 years in mid-April 378 2021. The role of the Gamma variant is also questioned, but a causal relationship cannot

be established. It is possible that, as the variant becomes more transmissible, there has
been an increase in cases among the population that has remained vulnerable to infection,
such as the economically active population.

382 The proportion of patients with comorbidities in the literature varies by wave and 383 region. Our analysis found an increase in hospitalizations of individuals without 384 comorbidities during the second wave, which is in agreement with an Indian study, but 385 differs from a Spanish cohort that found an increase in ICU admissions among individuals 386 with comorbidities. [19-22,24,25] These contradicting findings might be attributed to 387 socioeconomic factors and challenges with healthcare access, as developing countries 388 face more significant barriers to health care and possibly less diagnosis and control of 389 chronic diseases. The prevalence of Type 2 Diabetes Mellitus and cardiovascular diseases 390 have both decreased significantly, while the prevalence of obesity has increased and has 391 been associated with more severe disease, but not with mortality.

The proportion of patients who did not require oxygen support was lower in the second wave. These findings should be interpreted with caution, since oximeters for monitoring saturation at home were made available as part of the restructuring of the primary healthcare system. Improved assistance in these health units occurred, as did the provision of home oxygen therapy. Furthermore, during the second wave, a more pronounced scarcity of hospital beds was observed, leading to the prioritization of hospitalization for patients with heightened disease severity.

In this study, laboratory tests revealed increased inflammatory markers such as CRP, DHL, and ferritin levels in both waves, but they were significantly higher in the second one. Changes in D-dimer levels and lymphopenia were also found. These findings are consistent with previous studies, [20,21] which found that increasing CRP levels by one unit raises the probability of developing severe disease by 0.06%. CRP is more than a marker of inflammation; it is also capable of maintaining the inflammatory response by

attracting leukocytes to areas of inflammation and causing the release of pro-inflammatory
cytokines. It is reasonable to assume that high levels of CRP are associated with elevated
interleukin 6 (IL-6) levels, given that the CRP gene is predominantly activated by IL-6. [20]
Elevated serum levels of LDH, a protein present in the cell cytoplasm, may suggest tissue
injury or necrosis. According to previous studies, having high levels of LDH may increase
the risk of death by approximately four times. [17]

411 In contrast to the second wave's subjective perceptions, [11] there was no increase 412 in the severity of hospitalized cases or the number of deaths. The two waves had no 413 statistically significant difference in disease severity or outcome, and the survival curves 414 were similar. [11,24–26] Several factors might explain these findings, including an increase 415 in the number of beds, the use of high-flow nasal cannulas, and the learning curve in 416 disease management, which was associated with a standardized care protocol, enabling 417 an optimized clinical management throughout the pandemic, resulting in fatality rates lower 418 than previously reported in the country.

419 The first months of the pandemic in Brazil were primarily caused by two strains, 420 B.1.1.28 and B.1.133. The Gamma variant replaced the previous lineages in early 2021 421 and became the main variant in less than three months, [27] as this study also showed. 422 Unlike the first wave, in which the variant spread primarily from densely populated urban 423 areas, the second wave originated in the Amazon, a geographically remote area with 424 difficult access. The Gamma variant was estimated to have an effective higher median 425 reproductive number (Re) and was 1.56-3.06 times more transmissible than previous non-426 Gamma variants. [27] While earlier research has indicated elevated likelihoods of 427 hospitalization and admission to ICU among Gamma cases [3, 5, 28–31], it is noteworthy 428 that even though Gamma cases were predominant during the second wave, we did not 429 observe corresponding higher rates of ICU admissions or fatalities in our study. Other 430 studies also found differences in genotype prevalence across waves, including a decrease

in fatality rate following the emergence of VOC Alpha. [15] Although the Gamma variant
has spread to many countries, it has been identified mainly on the American continent
(with 58% of the cases in Brazil and 26% in the USA); [30] therefore, few studies have
compared the impact of its introduction in clinical and epidemiological aspects outside of
Brazil.

In the univariate analysis, age, male sex, fever, neurologic disease, Charlson Comorbidity Index score, obesity, and length of hospital stay were all associated with higher disease severity. These factors remained independent risk factors after the multivariate analysis, as shown in previous studies. [2,17,19,21,22]

This study has limitations, mainly due to its retrospective nature, which depends on accurate and comprehensive medical record entries. Moreover, the dynamic evolution of disease understanding and treatment, alongside fluctuations in bed availability to fulfill the demand for hospitalizations, may have an influence on certain outcomes. Additionally, we were unable to conduct a genetic analysis on the entire sample.

In conclusion, the COVID-19 pandemic has lasted for a prolonged period, marked by oscillations in cases termed waves. These fluctuations are frequently linked to the emergence of viral variants harboring mutations that enhance viral fitness, replicative capacity, and immune evasion, leading to increased infection rates and rapid spread. Nevertheless, Gamma VoC did not display any apparent greater virulence compared to the Wild strain, and the disease severity remained comparable to previous variants.

451

452

453 **Acknowledgments**

The authors would like to sincerely thank the Virology Laboratory of the Hospital de Clínicas at the Federal University of Paraná, the Genetics Department Laboratory of the Federal University of Paraná, and the Respiratory Virus and Measles Laboratory of

- 457 Fiocruz/RJ for their invaluable support, insightful information exchanges, and significant
- 458 contributions to this research. Your collaboration has greatly enriched the quality and depth
- 459 of our work.
- 460
- 461

462 **References**

- 463 1. WHO COVID-19 Dashboard. Geneva: World Health Organization, 2020. Available
 464 from: <u>https://covid19.who.int/</u>.
- 465
 2. Amin R, Sohrabi MR, Zali AR, Hannani K. Five consecutive epidemiological waves
 466 of COVID-19: a population-based cross-sectional study on characteristics, policies,
- 467 and health outcome. BMC Infect Dis. 2022 Dec 5;22(1):906. doi: 10.1186/s12879-

468 022-07909-y. PMID: 36471283; PMCID: PMC9721063.

- 469 3. de Souza UJB, Dos Santos RN, Campos FS, Lourenço KL, da Fonseca FG, Spilki
- 470 FR, Corona-Ômica Br/McTi Network. High Rate of Mutational Events in SARS-CoV-
- 471 2 Genomes across Brazilian Geographical Regions, February 2020 to June 2021.
- 472 Viruses. 2021 Sep 10;13(9):1806. doi: 10.3390/v13091806. PMID: 34578387;
- 473 PMCID: PMC8473193.
- 474
 4. Li J, Lai S, Gao GF, Shi W. The emergence, genomic diversity and global spread of
 475
 SARS-CoV-2. Nature. 2021 Dec;600(7889):408-418. doi: 10.1038/s41586-021-
- 476 04188-6. Epub 2021 Dec 8. PMID: 34880490.
- 5. Naveca FG, Nascimento V, de Souza VC, Corado AL, Nascimento F, Silva G, et al.
- 478 COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages
- 479 and P.1 emergence. Nat Med. 2021 Jul;27(7):1230-1238. doi: 10.1038/s41591-021-
- 480 01378-7. Epub 2021 May 25. PMID: 34035535.
- 481 6. Fujino T, Nomoto H, Kutsuna S, Ujiie M, Suzuki T, Sato R, et al. Novel SARS-CoV-2
 482 Variant in Travelers from Brazil to Japan. Emerg Infect Dis. 2021 Apr;27(4):1243–5.

- 483 doi: 10.3201/eid2704.210138. Epub 2021 Feb 10. PMID: 33567247; PMCID:
- 484 PMC8007308.
- 485
 7. Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease
 486
 2019 (COVID-19): A literature review. J Infect Public Health. 2020 May;13(5):667487
 673. doi: 10.1016/j.jiph.2020.03.019. Epub 2020 Apr 8. PMID: 32340833; PMCID:
 488
 486
 487
- 489 8. Ranzani OT, Bastos LSL, Gelli JGM, Marchesi JF, Baião F, Hamacher S, et al.
- 490 Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: a
- 491 retrospective analysis of nationwide data. Lancet Respir Med. 2021 Apr;9(4):407-
- 492 418. doi: 10.1016/S2213-2600(20)30560-9. Epub 2021 Jan 15. PMID: 33460571;
- 493 PMCID: PMC7834889.
- 494 9. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138
 495 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan,
- 496 China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
- 497 Erratum in: JAMA. 2021 Mar 16;325(11):1113. PMID: 32031570; PMCID:
- 498 PMC7042881.
- 499 10. Arias Ramos D, Restrepo Rueda DL, Rios Quintero EV, Olaya Gómez JC, Cortés
- 500 Bonilla I. Severe and critical COVID-19 in a tertiary center in Colombia, a
- 501 retrospective cross-sectional study. BMC Infect Dis. 2022 Mar 12;22(1):247. doi:
- 502 10.1186/s12879-022-07246-0. PMID: 35279082; PMCID: PMC8917827.
- 503 11. Bastos LS, Ranzani OT, Souza TML, Hamacher S, Bozza FA. COVID-19 hospital
- admissions: Brazil's first and second waves compared. Lancet Respir Med. 2021
- 505 Aug;9(8):e82-e83. doi: 10.1016/S2213-2600(21)00287-3. Epub 2021 Jul 15. PMID:
- 506 34273268; PMCID: PMC8279962.
- 507 12. WHO Working Group on the Clinical Characterisation and Management of COVID-
- 508 19 infection. A minimal common outcome measure set for COVID-19 clinical

509	research.	Lancet Infect D	is. 2020 Aug:2	20(8):e192-e197	. doi: 10.1016/S1473-
000	100001011.	Lanoot miloot D	10. 2020 / lug,2	-0(0).0102 0101	

- 510 3099(20)30483-7. Epub 2020 Jun 12. Erratum in: Lancet Infect Dis. 2020
- 511 Oct;20(10):e250. PMID: 32539990; PMCID: PMC7292605.
- 512 13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
- 513 prognostic comorbidity in longitudinal studies: development and validation. J
- 514 Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8. PMID:
- 515 3558716.
- 516 14. Adamoski D, Baura VA, Rodrigues AC, Royer CA, Aoki MN, Tschá MK, et al. SARS-
- 517 CoV-2 Delta and Omicron Variants Surge in Curitiba, Southern Brazil, and Its
- 518 Impact on Overall COVID-19 Lethality. Viruses. 2022 Apr 14;14(4):809. doi:

519 10.3390/v14040809. PMID: 35458539; PMCID: PMC9027352.

- 520 15. Perazzo H, Cardoso SW, Ribeiro MPD, Moreira R, Coelho LE, Jalil EM, et al;
- 521 RECOVER-SUS Brasil Group. In-hospital mortality and severe outcomes after
- 522 hospital discharge due to COVID-19: A prospective multicenter study from Brazil.
- 523 Lancet Reg Health Am. 2022 Jul;11:100244. doi: 10.1016/j.lana.2022.100244. Epub
- 524 2022 Apr 12. Erratum in: Lancet Reg Health Am. 2022 Jul;11:100300. PMID:
- 525 35434696; PMCID: PMC9001143.
- 52616. Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, et al. Predictors of527COVID-19 severity: A literature review. Rev Med Virol. 2021 Jan;31(1):1-10. doi:
- 528 10.1002/rmv.2146. Epub 2020 Jul 30. PMID: 32845042; PMCID: PMC7855377.
- 529 17. Liu W, Yang C, Liao YG, Wan F, Lin L, Huang X, et al. Risk factors for COVID-19
- 530 progression and mortality in hospitalized patients without pre-existing comorbidities.
- 531 J Infect Public Health. 2022 Jan;15(1):13-20. doi: 10.1016/j.jiph.2021.11.012. Epub
- 532 2021 Nov 18. PMID: 34861603; PMCID: PMC8598256.
- 533 18. Oliva-Sánchez PF, Vadillo-Ortega F, Bojalil-Parra R, Martínez-Kobeh JP, Pérez-
- 534 Pérez JR, Pérez-Avalos JL. Factores de riesgo para complicaciones graves de

535	COVID-19,	comparando	tres olas	epidemiológicas.	Un enfoque	e desde la atención

- 536 primaria en México [Risk factors for COVID-19 severe complications comparing
- 537 three major epidemiological waves: An approach from primary health care in
- 538 Mexico]. Aten Primaria. 2022 Nov;54(11):102469. Spanish. doi:
- 539 10.1016/j.aprim.2022.102469. Epub 2022 Sep 13. PMID: 36244180; PMCID:
- 540 PMC9468309.
- 541 19. Matysek A, Studnicka A, Smith WM, Hutny M, Gajewski P, Filipiak KJ, et al.
- 542 Influence of Co-morbidities During SARS-CoV-2 Infection in an Indian Population.
- 543 Front Med (Lausanne). 2022 Aug 1;9:962101. doi: 10.3389/fmed.2022.962101.
- 544 PMID: 35979209; PMCID: PMC9377050.
- 545 20. Mousavi SF, Ebrahimi M, Moghaddam SAA, Moafi N, Jafari M, Tavakolian A, et al.
- 546 Evaluating the characteristics of patients with SARS-CoV-2 infection admitted
- 547 during COVID-19 peaks: A single-center study. Vacunas. 2023 Jan-Mar;24(1):27-36.
- 548 doi: 10.1016/j.vacun.2022.08.002. Epub 2022 Aug 30. PMID: 36062028; PMCID:
- 549 PMC9424515.
- 550 21. Bhargava A, Fukushima EA, Levine M, Zhao W, Tanveer F, Szpunar SM, et al.
- 551 Predictors for Severe COVID-19 Infection. Clin Infect Dis. 2020 Nov 5;71(8):1962552 1968. doi: 10.1093/cid/ciaa674. PMID: 32472676; PMCID: PMC7314166.
- 553 22. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al; COVID-19
- 554 Lombardy ICU Network. Risk Factors Associated With Mortality Among Patients
- 555 With COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern Med. 2020
- 556 Oct 1;180(10):1345-1355. doi: 10.1001/jamainternmed.2020.3539. Erratum in:
- 557 JAMA Intern Med. 2021 Jul 1;181(7):1021. PMID: 32667669; PMCID:
- 558 PMC7364371.
- 23. Raboni SM, Neves VC, Silva RM, Breda GL, Ceregato AC, Broza TP, et al. High Flow Nasal Cannula Therapy in Patients With COVID-19: Predictive Response

- 561 Factors. Respir Care. 2022 Nov;67(11):1443-1451. doi: 10.4187/respcare.09764.
- 562 Epub 2022 Aug 9. PMID: 35944966.
- 563 24. Salyer SJ, Maeda J, Sembuche S, Kebede Y, Tshangela A, Moussif M, et al. The
- 564 first and second waves of the COVID-19 pandemic in Africa: a cross-sectional
- 565 study. Lancet. 2021 Apr 3;397(10281):1265-1275. doi: 10.1016/S0140-
- 566 6736(21)00632-2. Epub 2021 Mar 24. PMID: 33773118; PMCID: PMC8046510.
- 567 25. Carbonell R, Urgelés S, Rodríguez A, Bodí M, Martín-Loeches I, Solé-Violán J, et
- 568 al; COVID-19 SEMICYUC Working Group. Mortality comparison between the first
- and second/third waves among 3,795 critical COVID-19 patients with pneumonia
- admitted to the ICU: A multicentre retrospective cohort study. Lancet Reg Health
- 571 Eur. 2021 Dec;11:100243. doi: 10.1016/j.lanepe.2021.100243. Epub 2021 Nov 4.
- 572 PMID: 34751263; PMCID: PMC8566166.
- 573 26. Nath R, Gupta NK, Jaswal A, Gupta S, Kaur N, Kohli S, et al. Mortality among adult
- 574 hospitalized patients during the first wave and second wave of COVID-19 pandemic
- 575 at a tertiary care center in India. Monaldi Arch Chest Dis. 2021 Oct 11;92(2). doi:
- 576 10.4081/monaldi.2021.2034. PMID: 34634900.
- 577 27. Gräf T, Bello G, Naveca FG, Gomes M, Cardoso VLO, da Silva AF, et al; Brazilian
- 578 Ministry of Health COVID-19 Genomic Surveillance Network. Phylogenetic-based
- 579 inference reveals distinct transmission dynamics of SARS-CoV-2 lineages Gamma
- 580 and P.2 in Brazil. iScience. 2022 Apr 15;25(4):104156. doi:
- 581
 10.1016/j.isci.2022.104156. Epub 2022 Mar 26. PMID: 35368908; PMCID:
- 582 PMC8957357.
- 28. Lin L, Liu Y, Tang X, He D. The Disease Severity and Clinical Outcomes of the
 SARS-CoV-2 Variants of Concern. Front Public Health. 2021 Nov 30;9:775224. doi:
- 585 10.3389/fpubh.2021.775224. PMID: 34917580; PMCID: PMC8669511.

- 586 29. Martins AF, Zavascki AP, Wink PL, Volpato FCZ, Monteiro FL, Rosset C, et al.
- 587 Detection of SARS-CoV-2 lineage P.1 in patients from a region with exponentially
- 588 increasing hospitalisation rate, February 2021, Rio Grande do Sul, Southern Brazil.
- 589 Euro Surveill. 2021 Mar;26(12):2100276. doi: 10.2807/1560-
- 590 7917.ES.2021.26.12.2100276. PMID: 33769251; PMCID: PMC7995561.
- 591 30. O'Toole Á, Scher E, Underwood A, Jackson B, Hill V, McCrone JT, et al. Assignment
- 592 of epidemiological lineages in an emerging pandemic using the pangolin tool. Virus
- 593 Evol. 2021 Jul 30;7(2):veab064. doi: 10.1093/ve/veab064. PMID: 34527285;
- 594 PMCID: PMC8344591.
- 595 31. Funk T, Pharris A, Spiteri G, Bundle N, Melidou A, Carr M, et al; COVID study
- 596 groups. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1:
- 597 data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Euro Surveill. 2021
- 598 Apr;26(16):2100348. doi: 10.2807/1560-7917.ES.2021.26.16.2100348. PMID:
- 599 33890566; PMCID: PMC8063589.
- 600
- 601

602 Supporting information

S1 Figure. ROC of laboratory parameters – Creatinine, Lactate dehydrogenase, Ferritin, CRP and D Dimer - in predicting the in-hospital mortality of COVID-19 patients. Note: ROC, receiver operating
 characteristic; AUC, area under the ROC curve; CRP, C-reactive protein.